Niu Jiali, Chen Hongjun, Chen Kaixia, Liu Yin, Ju Feng, Xue Ting, Yin Dengyang, Li Chaoqun, Yin Chunxia, Jiao Lingyun, Zhao Guangyu, Huang Jixun
Department of Clinical Pharmacy.
Department of Pharmacy, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
Medicine (Baltimore). 2020 Nov 25;99(48):e23377. doi: 10.1097/MD.0000000000023377.
We aimed to conduct a meta-analysis to assess the effect of pharmaceutical care on the treatment of coronavirus disease 2019 (COVID-19).
All case-controlled studies related to pharmaceutical care on the treatment of COVID-19 will be included in this review. We will use index words related to pharmaceutical care and COVID-19 to perform literature searches in PubMed, Embase, MEDLINE, CNKI, and Wanfang databases, to include articles indexed as of October 20, 2020 in English and Chinese language. Two reviewers will select trials independently for inclusion and assess trial quality. Two pairs of review authors will independently extract information for each included trials. Primary outcomes are clinical outcomes, average hospital stays, costs, patient satisfaction, and incidence of adverse drug reactions. We will evaluate the risk of bias of the included studies based on Cochrane assessment tool. Revman 5.3 (the Cochrane collaboration, Oxford, UK) will be used for heterogeneity assessment, generating funnel-plots, data synthesis, subgroup analysis, and sensitivity analysis.
We will provide targeted and practical results assessing the effect of pharmaceutical care on the treatment of COVID-19.
The stronger evidence about the effect of pharmaceutical care on the treatment of COVID-19 will be provided for clinicians.
PROSPERO CRD42020214223 ETHICS AND DISSEMINATION:: There is no need for ethical approval, and the review will be reported in a peer-reviewed journal.
我们旨在进行一项荟萃分析，以评估药学服务对2019冠状病毒病（COVID-19）治疗的效果。
本综述将纳入所有与药学服务对COVID-19治疗相关的病例对照研究。我们将使用与药学服务和COVID-19相关的关键词在PubMed、Embase、MEDLINE、中国知网和万方数据库中进行文献检索，以纳入截至2020年10月20日索引的中英文文章。两名评审员将独立选择试验纳入并评估试验质量。两对评审作者将独立为每个纳入试验提取信息。主要结局为临床结局、平均住院时间、费用、患者满意度和药物不良反应发生率。我们将根据Cochrane评估工具评估纳入研究的偏倚风险。将使用Revman 5.3（Cochrane协作网，英国牛津）进行异质性评估、生成漏斗图、数据合成、亚组分析和敏感性分析。
我们将提供有针对性且实用的结果，以评估药学服务对COVID-19治疗的效果。
将为临床医生提供关于药学服务对COVID-19治疗效果的更有力证据。
PROSPERO CRD42020214223 伦理与传播：无需伦理批准，本综述将在同行评审期刊上发表。
